Previous 10 | Next 10 |
Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update PR Newswire NEW YORK , Aug. 9, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of ...
Delcath Systems to File Its Second Quarter 2023 10-Q the Week of August 7 and Expects to Host a Conference Call the Following Week PR Newswire NEW YORK , Aug. 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused...
2023-07-05 10:00:00 ET Summary We've compiled a list of June Investment Picks that you may have missed. Some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come by in today's market environment. The investment ideas featured h...
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEW YORK , June 21, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of p...
2023-06-20 09:18:23 ET Delcath Systems ( NASDAQ: DCTH ) appoints Dr. Vojislav "Vojo" Vukovic as its new chief medical officer. Dr. Vukovic is an experienced drug development executive with a distinguished career in cancer research and global clinical development...
Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer PR Newswire NEW YORK , June 20, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and m...
Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance PR Newswire NEW YORK , June 7, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of prim...
2023-06-01 03:00:29 ET Summary Delcath Systems is close to gaining FDA approval for its HEPZATO KIT, a minimally invasive liver cancer treatment. The company is well-funded and prepared for commercial operations in the U.S. and Europe, with plans to partner with medical centers an...
2023-05-12 10:13:08 ET Delcath Systems Inc. (DCTH) Q1 2023 Earnings Conference Call May 12, 2023 8:30 am ET Company Participants Gerard Michel - Chief Executive Officer Anthony Dias - Vice President, Finance Kevin Muir - General Manager, U.S. Interventional Oncol...
2023-05-11 17:35:17 ET Delcath Systems ( NASDAQ: DCTH ) is scheduled to announce Q1 earnings results on Friday, May 12th, after market close. The consensus EPS Estimate is -$0.58 (+42.0% Y/Y) and the consensus Revenue Estimate is $0.79M (+107.9% Y/Y). Over the last 1 y...
News, Short Squeeze, Breakout and More Instantly...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 5, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024...
2024-07-16 23:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 07:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...